MADDEN SECURITIES Corp Reduces Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

MADDEN SECURITIES Corp lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) by 2.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 854 shares of the medical research company’s stock after selling 25 shares during the period. MADDEN SECURITIES Corp’s holdings in Thermo Fisher Scientific were worth $470,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of TMO. Verity & Verity LLC boosted its holdings in shares of Thermo Fisher Scientific by 2.8% in the 2nd quarter. Verity & Verity LLC now owns 1,234 shares of the medical research company’s stock valued at $670,000 after acquiring an additional 34 shares during the last quarter. SVB Wealth LLC raised its position in Thermo Fisher Scientific by 3.8% during the second quarter. SVB Wealth LLC now owns 7,390 shares of the medical research company’s stock worth $4,015,000 after acquiring an additional 273 shares during the period. Sepio Capital LP grew its holdings in shares of Thermo Fisher Scientific by 4.5% during the third quarter. Sepio Capital LP now owns 787 shares of the medical research company’s stock worth $399,000 after buying an additional 34 shares in the last quarter. Coston McIsaac & Partners purchased a new stake in shares of Thermo Fisher Scientific during the second quarter worth $44,000. Finally, Ameritas Advisory Services LLC grew its holdings in shares of Thermo Fisher Scientific by 5.3% during the third quarter. Ameritas Advisory Services LLC now owns 4,607 shares of the medical research company’s stock worth $2,337,000 after buying an additional 230 shares in the last quarter. Hedge funds and other institutional investors own 85.92% of the company’s stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock traded down $9.75 during midday trading on Friday, reaching $547.34. The company’s stock had a trading volume of 1,947,936 shares, compared to its average volume of 1,498,879. The firm has a market capitalization of $210.96 billion, a PE ratio of 31.05, a P/E/G ratio of 1.88 and a beta of 0.79. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.15 and a current ratio of 1.48. Thermo Fisher Scientific Inc. has a fifty-two week low of $475.77 and a fifty-two week high of $618.35. The stock’s 50 day simple moving average is $565.91 and its 200 day simple moving average is $545.06.

Thermo Fisher Scientific (NYSE:TMO – Get Rating) last released its quarterly earnings results on Wednesday, February 1st. The medical research company reported $5.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.19 by $0.21. The business had revenue of $11.45 billion during the quarter, compared to the consensus estimate of $10.41 billion. Thermo Fisher Scientific had a return on equity of 21.42% and a net margin of 15.47%. The business’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $6.54 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.72 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 14th. Stockholders of record on Wednesday, March 15th will be paid a dividend of $0.35 per share. This represents a $1.40 annualized dividend and a dividend yield of 0.26%. The ex-dividend date of this dividend is Tuesday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.30. Thermo Fisher Scientific’s payout ratio is 7.94%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Cowen upped their target price on shares of Thermo Fisher Scientific from $690.00 to $711.00 and gave the stock an “outperform” rating in a report on Thursday, February 2nd. SVB Leerink upped their price objective on shares of Thermo Fisher Scientific from $620.00 to $630.00 and gave the company an “outperform” rating in a report on Thursday, February 2nd. Royal Bank of Canada started coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, December 6th. They set an “outperform” rating and a $661.00 target price for the company. Citigroup raised their target price on shares of Thermo Fisher Scientific from $650.00 to $700.00 and gave the company a “buy” rating in a report on Thursday, February 2nd. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, December 13th. They set a “buy” rating and a $620.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $647.00.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 7,500 shares of the business’s stock in a transaction dated Monday, March 13th. The shares were sold at an average price of $544.49, for a total value of $4,083,675.00. Following the completion of the transaction, the chief executive officer now owns 66,655 shares of the company’s stock, valued at approximately $36,292,980.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Marc N. Casper sold 7,500 shares of the business’s stock in a transaction dated Monday, March 13th. The shares were sold at an average price of $544.49, for a total value of $4,083,675.00. Following the completion of the transaction, the chief executive officer now owns 66,655 shares of the company’s stock, valued at approximately $36,292,980.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jim P. Manzi sold 1,000 shares of the business’s stock in a transaction dated Friday, February 3rd. The shares were sold at an average price of $584.56, for a total transaction of $584,560.00. Following the completion of the transaction, the director now directly owns 14,807 shares of the company’s stock, valued at approximately $8,655,579.92. The disclosure for this sale can be found here. Insiders sold 30,100 shares of company stock valued at $16,966,971 in the last 90 days. 0.43% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

(Get Rating)

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.